Skip to main content

Advertisement

Fig. 2 | BMC Neurology

Fig. 2

From: Dose effects of mycophenolate mofetil in Chinese patients with neuromyelitis optica spectrum disorders: a case series study

Fig. 2

Adjusted Hazard Risks for relapse after MMF initiation, according to the clinical characteristics and based on patients who received MMF for more than 6 months. NMOSD patients treated with the higher dose of MMF had a significantly lower risk of relapse (HR, 0.291; 95% confidence interval, 0.164–0.516; p < 0.0001). Significant risk factors for relapse in NMOSD patients were the presence of any systemic autoimmune disease (HR, 2.418; 95% confidence interval, 1.066–5.481; p = 0.0345) and an increased number of relapses before MMF initiation (HR, 1.117; 95% confidence interval, 1.018–1.227; p = 0.020). Other factors were determined to have little influence on the effect of MMF treatment

Back to article page